pexidartinib has been researched along with Colonic-Neoplasms* in 2 studies
2 other study(ies) available for pexidartinib and Colonic-Neoplasms
| Article | Year |
|---|---|
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Immunotherapy based on the immune checkpoint blockade has emerged as the most promising approach for cancer therapy. However, the proportion of colorectal cancer patients who benefit from immunotherapy is small due to the immunosuppressive tumor microenvironment. Hence, combination immunotherapy is an ideal strategy to overcome this limitation. In this study, we developed a novel combination of CSF-1R (colony-stimulating factor 1 receptor) inhibitor (PLX3397), oncolytic viruses, and anti-PD-1 antibody. Our results demonstrated that the triple treatment synergistically conferred significant tumor control and prolonged the survival of mouse models of colon cancer. Approximately 43% and 82% of mice bearing the CT26 and MC38 tumor, respectively, survived long term following the triple treatment. This combination therapy reprogrammed the immunosuppressive tumor microenvironment toward a CD8 Topics: Aminopyridines; Animals; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Colonic Neoplasms; Female; Flow Cytometry; Humans; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oncolytic Viruses; Programmed Cell Death 1 Receptor; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Microenvironment | 2019 |
[Pexidartinib inhibits the aggregation of monocytes into tumor microenvironment and reduces the number of M2 tumor-associated macrophages].
Topics: Aminopyridines; Animals; Cell Line, Tumor; Colonic Neoplasms; Flow Cytometry; Leukocytes, Mononuclear; Macrophages; Mice; Monocytes; Pyrroles; Tumor Microenvironment | 2019 |